Would you hold off using fam-trastuzumab deruxtecan-nxki in malignant pleural effusion?

No. While there may be a higher risk of higher-grade pulmonary adverse events in patients with pleural effusions, some of this is related to the impaired pulmonary function (e.g., loss of volume, lower flexibility of the lung tissue) and also the possible/probable involvement of intrapulmonary lymph...

My decision on whether or not to use T-DXd in this situation would heavily depend on the patient's comorbidities, symptoms, and other radiographic findings. If the patient's dyspnea related to malignant pleural effusion is relieved with thoracentesis, she has no prior history of pulmonary disorders,...